
PHARMACEUTICALS: RESTRICTIONS IN USE AND AVAILABILITY

**PHARMACEUTICALS:
RESTRICTIONS IN USE AND AVAILABILITY**

Prepared within the context of the United Nations publication

**"Consolidated List of Products whose Consumption and/or Sale
have been Banned, Withdrawn, Severely Restricted or Not
Approved by Governments"**



Update of the Fourteenth Issue

2010

**Essential Medicines and Pharmaceutical Policies
Quality Assurance and Safety: Medicines
Health Systems and Services**

© World Health Organization 2010

All rights reserved. Publications of the World Health Organization can be obtained from Marketing and Dissemination, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: 1). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to Marketing and Dissemination, at the above address (fax: +41 22 791 4806; email: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.

Printed in Switzerland.

Acknowledgements:

WHO expresses its sincere appreciation to the National Pharmacovigilance Centres and / or National Medicines Regulatory Agencies, for providing the information contained in this publication. Sincere thanks are due to Ms Cecilia Biriell, the Uppsala Monitoring Centre, Sweden, and to Ms Jackie Lu and Mr Dominick Bailey, University of Maryland-Baltimore, USA for their assistance with content editing, layout and technical support.

This text is the update to the Fourteenth Issue of the United Nations Consolidated List of Products whose Consumption and/or Sale have been Banned, Withdrawn, Severely Restricted or Not Approved by Governments - Pharmaceuticals (UN General Assembly Resolutions 37/137, 1982; 38/149, 1983; 39/229, 1984; 44/226, 1989). It is offered as a service to drug regulators, the pharmaceutical industry, and to everyone interested in assuring the safe and rational use of drugs. It complements and consolidates other drug-related information issued by the World Health Organization, including the WHO Rapid Alerts, WHO Pharmaceuticals Newsletter and the quarterly subscription journal WHO Drug Information.

Scope and presentation

This volume presents information on new national regulatory decisions and on voluntary withdrawal of products by manufacturers on grounds of safety from 2009, 2010 (up to May 2010), and earlier years that had not been included in the last update.

Products are listed alphabetically within sections; International Nonproprietary Names (INNs) have been used whenever possible. Each product entry includes, where available, the Chemical Abstracts Service registry number (CAS number); synonyms including other generic names and chemical names; the effective date on which the regulation came into force; a summary of regulatory measures taken by governments; brief explanatory comments where necessary; and legal and bibliographical references.

While the information cannot be regarded as exhaustive, either in terms of products or regulatory measures, it covers regulatory actions taken by a total of 38 governments on 99 products. It should be noted, nonetheless, that decisions taken by a limited number of governments on a specific product may not be representative of the positions of other governments. Moreover, the fact that a given product is not listed as regulated by a country does not necessarily mean that it is permitted in that country; it may mean that the relevant regulatory decision has not been communicated to WHO or that the product has not been submitted for registration. The efficacy of products listed is not addressed, but is an aspect that may be crucial when a government is considering regulatory action.

Criteria for the inclusion of products in the Consolidated List were developed in 1985 and revised in the light of the comments received from governments. However, governments' interpretation of the criterion "severely restricted", in particular, continues to vary widely, leading to considerable unevenness in reporting. When necessary, additional information and/or clarification have been requested from governments; products which clearly do not meet the criteria have been omitted after consultation with governments. Information received from non-governmental organizations has, in each case, been verified with governments.

The information provided also includes references to relevant legal or statutory documents that enable the user to ascertain the legal context and scope of the regulations. Such references cannot be given for most entries relating to specific pharmaceutical products since the relevant licenses are often made or amended by an administrative decision which is not published. Brief explanatory comments also appear, where necessary, to clarify certain regulatory actions and put them into broader context.

Table of Contents

Alphabetical listing

Monocomponent Products

Aliskiren.....	1
Aprotinin	1
Becaplermin	2
Benzyl alcohol	2
Bufexamac	3
Cabergoline	3
Carbinoxamine	4
Ceftriaxone	4
Chloroquine	5
Chromic-phosphate-P-32	6
Clindamycin.....	6
Clopidogrel	6
Clozapine	7
Colchicine.....	8
Cyproterone	9
Deferasirox.....	9
Desmopressin	10
Dextropropoxyphene	10
Efalizumab	11
Etoricoxib	13
Etravirine	13
Fentanyl	13
Flecainide.....	14
Gadolinium	14
Gadoversetamide	15
Goserelin	15
Human Chorionic Gonadotropin Hormone	16
Human immune globulin.....	16
Iron sucrose	17
Isotretinoin.....	17
Ivermectin.....	18
Ketoprofen.....	18
Laronidase	19
Letrozole	19
Mefenamic acid	19
Mefloquine.....	20
Metamizole.....	20
Methylphenidate	20

Methylthioninium chloride	21
Metoclopramide	21
Misoprostol	22
Moxifloxacin	22
Mycophenolate mofetil	22
Nifuroxazine	23
Nimesulide	23
Nitrous oxide	25
Norfloxacin	26
Orciprenaline	26
Pergolide	26
Phenazone	27
Phenylpropanolamine	27
Pimecrolimus	28
Piroxicam	28
Promethazine	28
Propylthiouracil	29
Pseudoephedrine	29
Rimonabant	30
Sibutramine	30
Sodium phosphate	32
<i>Stichopus</i> sp. (<i>S. horrens</i> , <i>S. variegatus</i>)	33
Tacrolimus	33
Telithromycin	34
Thalidomide	34
Tibolone	35
Tinzaparin	35
Tiotropium	36
Toremifene	36
Tramadol	37
Triamcinolone	37
Vincristine	37
Zinc-containing intranasal products	38

Combination Products

Baithach	39
Belly cut capsules	39
Chloral hydrate and triclofos	39
Chloroproguanil and dapsone	40
Clindamycin and miconazole	40
Dietary supplements	41
Dismectide	41
Ephedrine and kava kava products	41
Levonorgestrel + Intra-uterine Contraceptive Devices (IUCDs)	42
Neomycin sulphate, polymyxine sulphate and nystatin	42

Paracetamol and pseudoephedrine	43
Rhinoil	43
Tadimax	43
Vitrum Beauty Elite	44

Group Products

Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists	45
Nasal sprays	45
Codeine and dihydrocodeine-containing medicines	46
Cough and cold medicines	46
Ergot-derived dopamine agonists	48
Erythropoiesis-stimulating agents	49
Herbal cold and flu products	49
Inhalers with CFC propellants	50
Long-acting beta-agonists	50
Oral preparations containing alcohol	51
Salicylates	51
Short acting beta-agonists (SABAs)	51
Vitamins	52

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_29012

